European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

  • Giovanni B. Frisoni
  • Cristina Festari
  • Federico Massa
  • Matteo Cotta Ramusino
  • Stefania Orini
  • Dag Aarsland
  • Federica Agosta
  • Claudio Babiloni
  • Barbara Borroni
  • Stefano F. Cappa
  • Lutz Froelich
  • Valentina Garibotto
  • Alexander Haliassos
  • Frank Jessen
  • Anita Kamondi
  • Roy PC Kessels
  • Silvia D. Morbelli
  • John T. O'Brien
  • Markus Otto
  • Armand Perret-Liaudet
  • Francesca B. Pizzini
  • Mathieu Vandenbulcke
  • Ritva Vanninen
  • Frans Verhey
  • Meike W. Vernooij
  • Tarek Yousry
  • Mercè Boada Rovira
  • Bruno Dubois
  • Jean Georges
  • Oskar Hansson
  • Craig W. Ritchie
  • Philip Scheltens
  • Wiesje M. van der Flier
  • Flavio Nobili
The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.
OriginalsprogEngelsk
TidsskriftThe Lancet Neurology
Vol/bind23
Udgave nummer3
Sider (fra-til)302-312
Antal sider11
ISSN1474-4422
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
LF and FJ were delegated from the European Alzheimer Disease Consortium; FV and MV from the European Association of Geriatric Psychiatry; KSF and FA from the European Academy of Neurology; SDM and VG from the European Association of Nuclear Medicine; DA and JTO from the European DLB Consortium; CB and AK from the Europe, Middle East, and Africa Chapter of the International Federation of Clinical Neurophysiology; TY and MWV from the European Society of Neuroradiology; SFC and RPCK from the Federation of the European Societies of Neuropsychology; BB and MO from the European FTD network; AH and AP-L from the International Federation of Clinical Chemistry; FBP and RV from the European Union of Medical Specialists. We acknowledge unrestricted grants from F Hoffmann-La Roche, Biogen International, Eisai Europe, Life Molecular Imaging, and OM Pharma Suisse. The funders had no role in the conception, design, and implementation of the project nor in data collection, data analysis, interpretation, or discussion of the results. Funders had no privileged access to the project's outputs at any stage.

Funding Information:
LF and FJ were delegated from the European Alzheimer Disease Consortium; FV and MV from the European Association of Geriatric Psychiatry; KSF and FA from the European Academy of Neurology; SDM and VG from the European Association of Nuclear Medicine; DA and JTO from the European DLB Consortium; CB and AK from the Europe, Middle East, and Africa Chapter of the International Federation of Clinical Neurophysiology; TY and MWV from the European Society of Neuroradiology; SFC and RPCK from the Federation of the European Societies of Neuropsychology; BB and MO from the European FTD network; AH and AP-L from the International Federation of Clinical Chemistry; FBP and RV from the European Union of Medical Specialists. We acknowledge unrestricted grants from F Hoffmann-La Roche, Biogen International, Eisai Europe, Life Molecular Imaging, and OM Pharma Suisse. The funders had no role in the conception, design, and implementation of the project nor in data collection, data analysis, interpretation, or discussion of the results. Funders had no privileged access to the project's outputs at any stage.

Publisher Copyright:
© 2024 Elsevier Ltd

ID: 384254871